Article
Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2015
Maitland Michael L, Xu Chun-Fang, Cheng Yu-Ching, Kistner-Griffin Emily, Ryan Kathleen A, Karrison Theodore G, Das Soma, Torgerson Dara, Gamazon Eric R, Thomeas Vasiliki, Levine Matthew R, Wilson Paul A, Bing Nan, Liu Yuan, Cardon Lon R, Pandite Lini N, O'Connell Jeffrey R, Cox Nancy J, Mitchell Braxton D, Ratain Mark J, Shuldiner Alan R
Abstract excerpt
PURPOSE: VEGF receptor (VEGFR) kinases are important drug targets in oncology that affect function of systemic endothelial cells. To discover genetic markers that affect VEGFR inhibitor pharmacodynamics, we performed a genome-wide association study of serum soluble vascular VEGFR2 concentrations [sVEGFR2], a pharmacodynamic biomarker for VEGFR2 inhibitors. EXPERIMENTAL DESIGN: We conducted a genome-wide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
